| Core
Business: |
Specialty
pharmaceutical company with expertise in transdermal drug delivery |

Vivelle-Dot®,
the most prescribed transdermal estrogen therapy product
in the U.S.
|
| Year
of IPO: |
1988 |
| Headquarters: |
Noven
Pharmaceuticals, Inc
11960 SW 144th Street
Miami, Florida 33186
305-253-5099
|
Chairman
(Non-executive): |
Wayne
P. Yetter |
President
&
Chief Executive Officer: |
Peter
C. Brandt |
Vice
President &
Chief Financial Officer: |
Michael
D. Price |
Investor,
Media
and General Business Inquiries: |
Joseph
C. Jones
Vice President – Corporate Affairs
Noven Pharmaceuticals, Inc.
11960 SW 144th Street
Miami, Florida 33186
Ph: 305-253-1916
jjones@noven.com |
Licensing
and
Business Development
Inquiries: |
Pavan
Handa
Vice President Business Development
Ph: 305-964-3330
phanda@noven.com |
| Affiliated
Companies: |
Novogyne
Pharmaceuticals –
a womens health products company jointly owned by Noven and
Novartis Pharmaceuticals Corporation
Noven Therapeutics, LLC
(f/k/a
JDS Pharmaceuticals, LLC) –
a specialty pharmaceutical
company acquired by Noven in August 2007 |
| Employees:
|
Approximately
580 |
| NASDAQ
Symbol: |
NOVN
(Common Stock) |
| Shares
Outstanding: |
Approximately
25 million |
| Fiscal
Year End: |
December
31 |
|
| Key
Products: |
Pexeva®
(paroxetine
mesylate)
Selective Serotonin Reuptake Inhibitor (SSRI)
Marketed by Noven Therapeutics, LLC
Lithobid®
(lithium
carbonate)
Extended Release Lithium (U.S.)
Marketed
by Noven Therapeutics, LLC
Daytrana
(methylphenidate
transdermal system)
Once-daily Transdermal Methylphenidate Patch (U.S.)
Marketed by Shire plc
Vivelle-Dot®
(estradiol transdermal system)
Worlds Smallest Transdermal Estrogen Patch (U.S. & Canada)
Marketed by Novogyne Pharmaceuticals
CombiPatch®
(estradiol/norethindrone
acetate)
Combination Estrogen/Progestogen Patch (U.S.)
Marketed by Novogyne Pharmaceuticals
Estradot®
(estradiol
transdermal system)
World's Smallest Transdermal Estrogen Patch (Europe & elsewhere)
Marketed
by Novartis
Estalis®
(estradiol/norethindrone
acetate)
Combination Estrogen/Progestogen Patch (Europe & elsewhere)
Marketed by Novartis
Menorest®
(estradiol
transdermal system)
Advanced Transdermal Estrogen Patch (Europe & elsewhere)
Marketed by Novartis
|
| Research & Development: |
Oral
products in development for psychiatric disorders, a
non-hormonal oral product for menopausal symptoms, and a range
of transdermal drug delivery systems for central nervous system
disorders and other therapeutic areas. |
Transfer
Agent
& Registrar: |
American Stock Transfer and Trust Company
59 Maiden Lane
New York, New York 10038 |
| Independent
Auditors: |
Deloitte & Touche LLP
200 South Biscayne Boulevard
Suite 400
Miami, Florida 33131-2310 |
Patient,
Physician
and Pharmacist Inquiries
Regarding Pexeva®
and
Lithobid®: |
Kendle
International, Inc.
441 Vine Street
Suite 1200
Cincinnati, Ohio 45202
Attn: Safety Department
Ph: 800-455-8070
|
Patient,
Physician
and Pharmacist Inquiries
Regarding Vivelle®,
Vivelle-Dot® or
CombiPatch®: |
Customer
Interaction Center
Novartis Pharmaceuticals Corporation
One Health Plaza
Building 122
East Hanover, New Jersey 07936
Ph: 888-669-6682
Fax: 973-781-3115
Click
here for E-mail Contact |
Patient,
Physician
and Pharmacist Inquiries
Regarding Daytrana: |
Shire
US Inc.
725 Chesterbrook Blvd.
Wayne, PA 19087
Ph: 800-828-2088 |